A group of scientific and technological experts with international experience founded CH Biomedical, Inc. (CHB) in 2008 with the intention of improving the survival and quality of life for patients with end-stage heart failure. CH Biomedical's corporate headquarters are in Suzhou Industrial Park, and its wholly-owned subsidiary, CH Biomedical USA, Inc., is based in Los Angeles, California. Modern ventricular assist devices (VADs) are the focus of research and development at CH Biomedical, which also works to promote their commercialization and benefit patients with end-stage heart failure.